Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. The company develops zipalertinib, a bioavailable small molecule in Phase 3 trial for the treatment of patients with non-small cell lung cancer; CLN-978, a T cell engager to treat systemic lupus erythematosus and rheumatoid arthritis; and CLN-619, a monoclonal antibody in Phase 1 trial for the treatment of solid tumors and multiple myeloma. Its development products also include CLN-049, a humanized bispecific antibody in Phase 1 trial for the treatment of acute myeloid leukemia (AML) or myelodysplastic syndrome, as well as measurable residual disease positive AML; and CLN-617, a fusion protein in Phase 1 trial for the treatment of solid tumors. It has a collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop zipalertinib. The company was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Cullinan Therapeutics Inc.

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Schrodinger (SDGR – Research Report), Lexicon Pharmaceuticals (LX...

Analysts Offer Insights on Healthcare Companies: Schrodinger (SDGR), Lexicon Pharmaceuticals (LXRX) and Cullinan Management (CGEM)

Jefferies analyst Charles Brennan maintained a Hold rating on Capgemini SE today and set a price target of €130.00. The company’s shares closed las...

Jefferies Remains a Hold on Capgemini SE (0HAZ)

In a report released today, Richard Nguyen from Bernstein maintained a Buy rating on Capgemini SE, with a price target of €225.00. The company’s sh...

New Buy Rating for Capgemini SE (0HAZ), the Technology Giant

In a report released today, Adam Wood from Morgan Stanley maintained a Hold rating on Capgemini SE, with a price target of €145.00. The company’s s...

Current Quarter	$-0.84	Next Quarter	$-0.91
Current Year	$-3.57	Next Year	$-3.45
QoQ Growth	-8.3%	YoY Growth	+3.4%
3Y EPS CAGR	+0.0%	Target Price	$26.25
Consensus	Buy	Upside	+177.2%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	CGEM	$9.47	+8.60%	2.12M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	CGEM	$9.47	+8.6%	2.12M
3
4
5
6

CGEM

CGEM

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Cullinan Therapeutics Inc. Data in Excel

Get Cullinan Therapeutics Inc. Data in Excel